» Articles » PMID: 24067086

Development of RNA Aptamers Targeting Ebola Virus VP35

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2013 Sep 27
PMID 24067086
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Viral protein 35 (VP35), encoded by filoviruses, is a multifunctional dsRNA binding protein that plays important roles in viral replication, innate immune evasion, and pathogenesis. The multifunctional nature of these proteins also presents opportunities to develop countermeasures that target distinct functional regions. However, functional validation and the establishment of therapeutic approaches toward such multifunctional proteins, particularly for nonenzymatic targets, are often challenging. Our previous work on filoviral VP35 proteins defined conserved basic residues located within its C-terminal dsRNA binding interferon (IFN) inhibitory domain (IID) as important for VP35 mediated IFN antagonism and viral polymerase cofactor functions. In the current study, we used a combination of structural and functional data to determine regions of Ebola virus (EBOV) VP35 (eVP35) to target for aptamer selection using SELEX. Select aptamers, representing, two distinct classes, were further characterized based on their interaction properties to eVP35 IID. These results revealed that these aptamers bind to distinct regions of eVP35 IID with high affinity (10-50 nM) and specificity. These aptamers can compete with dsRNA for binding to eVP35 and disrupt the eVP35-nucleoprotein (NP) interaction. Consistent with the ability to antagonize the eVP35-NP interaction, select aptamers can inhibit the function of the EBOV polymerase complex reconstituted by the expression of select viral proteins. Taken together, our results support the identification of two aptamers that bind filoviral VP35 proteins with high affinity and specificity and have the capacity to potentially function as filoviral VP35 protein inhibitors.

Citing Articles

Aptamers: precision tools for diagnosing and treating infectious diseases.

Sujith S, Naresh R, Srivisanth B, Sajeevan A, Rajaramon S, David H Front Cell Infect Microbiol. 2024; 14:1402932.

PMID: 39386170 PMC: 11461471. DOI: 10.3389/fcimb.2024.1402932.


RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens.

Kola N, Patel D, Thakur A Methods Mol Biol. 2024; 2813:321-370.

PMID: 38888787 DOI: 10.1007/978-1-0716-3890-3_21.


Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.

Zhang Y, Juhas M, Kwok C Trends Biotechnol. 2022; 41(4):528-544.

PMID: 35995601 PMC: 9340053. DOI: 10.1016/j.tibtech.2022.07.012.


Applications in Which Aptamers Are Needed or Wanted in Diagnostics and Therapeutics.

Bruno J Pharmaceuticals (Basel). 2022; 15(6).

PMID: 35745612 PMC: 9228505. DOI: 10.3390/ph15060693.


Biodiagnostics in an era of global pandemics-From biosensing materials to data management.

Broza Y, Haick H View (Beijing). 2021; 3(2):20200164.

PMID: 34766159 PMC: 8441813. DOI: 10.1002/VIW.20200164.


References
1.
Fabozzi G, Nabel C, Dolan M, Sullivan N . Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol. 2011; 85(6):2512-23. PMC: 3067942. DOI: 10.1128/JVI.01160-10. View

2.
Jhaveri S, Ellington A . In vitro selection of RNA aptamers to a protein target by filter immobilization. Curr Protoc Mol Biol. 2008; Chapter 24:Unit 24.3. DOI: 10.1002/0471142727.mb2403s52. View

3.
Warfield K, Aman M . Advances in virus-like particle vaccines for filoviruses. J Infect Dis. 2011; 204 Suppl 3:S1053-9. PMC: 3189993. DOI: 10.1093/infdis/jir346. View

4.
Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

5.
McCaskill J . The equilibrium partition function and base pair binding probabilities for RNA secondary structure. Biopolymers. 1990; 29(6-7):1105-19. DOI: 10.1002/bip.360290621. View